Last reviewed 2026-04-19 · How we verify

MIVOTILATE

Phase 2 active Small molecule

MIVOTILATE is a drug. It is currently in Phase 2 development.

MIVOTILATE works by binding to specific biological molecules to produce a therapeutic effect.

MIVOTILATE is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it has not been approved by the FDA for any indications. As a small molecule, it is likely to work by interacting with specific biological molecules to produce a therapeutic effect. However, without more information, it is difficult to provide a comprehensive summary of its mechanism of action and safety considerations. Further research is needed to fully understand MIVOTILATE's properties and potential uses.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	MIVOTILATE
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine MIVOTILATE as a key that fits into a lock on a specific protein. When it binds, it can either block or enhance the protein's activity, leading to changes in the body's chemistry that can help treat a disease or condition. This is a simplified explanation of how small molecules like MIVOTILATE can interact with biological systems to produce a therapeutic effect.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MIVOTILATE CI brief — competitive landscape report
MIVOTILATE updates RSS · CI watch RSS

Frequently asked questions about MIVOTILATE

What is MIVOTILATE?

MIVOTILATE is a Small molecule drug.

How does MIVOTILATE work?

MIVOTILATE works by binding to specific biological molecules to produce a therapeutic effect.

What development phase is MIVOTILATE in?

MIVOTILATE is in Phase 2.

Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing